CD8+HLADR+ Regulatory T Cells Change With Aging: They Increase in Number, but Lose Checkpoint Inhibitory Molecules and Suppressive Function
CD4+ regulatory T cells have been intensively studied during aging, but little is still known about age-related changes of other regulatory T cell subsets. It was, therefore, the goal of the present study to analyze CD8+human leukocyte antigen–antigen D related (HLADR)+ T cells in old age, a cell population reported to have suppressive activity and to be connected to specific genetic variants. We demonstrate a strong increase in the number of CD8+HLADR+ T cells with age in a cohort of female Sardinians as well as in elderly male and female persons from Austria. We also show that CD8+HLADR+ T cells lack classical activation molecules, such as CD69 and CD25, but contain increased numbers of checkpoint inhibitory molecules, such as cytotoxic T lymphocyte-associated antigen 4, T cell immunoglobulin and mucin protein-3, LAG-3, and PD-1, when compared with their HLADR− counterparts. They also have the capacity to inhibit the proliferation of autologous peripheral blood mononuclear cells. This suppressive activity is, however, decreased when CD8+HLADR+ T cells from elderly persons are analyzed. In accordance with this finding, CD8+HLADR+ T cells from persons of old age contain lower percentages of checkpoint inhibitory molecules than young controls. We conclude that in spite of high abundance of a CD8+ regulatory T cell subset in old age its expression of checkpoint inhibitory molecules and its suppressive function on a per cell basis are reduced. Reduction of suppressive capacity may support uncontrolled subclinical inflammatory processes referred to as “inflamm-aging.”
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1016/j.cell.2013.08.041
- https://doi.org//10.1084/jem.148.5.1440
- https://doi.org//10.1084/jem.150.2.246
- https://doi.org//10.4049/jimmunol.176.8.4622
- https://doi.org//10.4049/jimmunol.1401490
- https://doi.org//10.1084/jem.143.6.1391
- https://doi.org//10.4049/jimmunol.167.3.1245
- https://doi.org//10.1084/jem.193.11.1295
- https://doi.org//10.1182/blood.V98.9.2736
- https://doi.org//10.1038/ni904
- https://doi.org//10.1126/science.1079490
- https://doi.org//10.1159/000355303
- https://doi.org//10.1097/00007890-200004150-00016
- https://doi.org//10.1172/JCI17935
SHARE
Usage metrics

AUTHORS (12)
- SYStella Lukas YaniMKMichael KellerFMFranz Leonard MelzerBWBirgit WeinbergerLPLuca PangrazziSSSieghart SopperKTKlemens TriebMLMonia LobinaVOValeria OrrùEFEdoardo FiorilloFCFrancesco CuccaBGBeatrix Grubeck-Loebenstein
CATEGORIES
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity